Skip to main content

Advertisement

Table 1 Clinicopathologic features among 18 patients for acquired MET amplification

From: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Characteristics Number Percentage (%)
Gender
Male 7 38.9
Female 11 61.1
Age (years)
Mean 57 years  
< 60 10 55.6
≥ 60 8 44.4
ECOG PS
0–1 18 100
2 0 0
Histologic type
Adenocarcinoma 16 88.9
Other 2 11.1
Smoking status
No 12 66.7
Yes 6 33.3
Type of EGFR mutation
19 deletion 2 11.1
21L858R 16 88.9
Type of EGFR-TKIs
Gefitinib 10 55.6
Elrotinib 3 16.7
Icotinib 5 27.8
Treatment lines of EGFR-TKI
First line 12 66.7
Second line or more 6 33.3
Met amplification
> 5 12 66.7
2.2–5 4 22.2
1.8–2.2 2 11.1
Receiving crizotinib
Yes 14 77.8
No 4 22.2